What is daprodustat, and what is it used for?
Daprodustat is a drug used to treat anemia in people with chronic kidney disease (CKD). It works by affecting how the body produces erythropoietin, a hormone that helps the body make red blood cells [1].
How does daprodustat work (mechanism)?
Daprodustat is designed to increase red blood cell production by influencing oxygen-sensing pathways that regulate erythropoietin levels, which can lead to higher hemoglobin in patients with CKD-related anemia [1].
Is daprodustat used in dialysis patients and non-dialysis CKD?
Daprodustat is used for anemia in CKD, which includes both people on dialysis and people not on dialysis, depending on local prescribing guidance and approval labeling [1].
How does daprodustat compare with other anemia treatments in CKD?
In CKD anemia care, common options include erythropoiesis-stimulating agents (ESAs) like epoetin and darbepoetin, and iron supplementation. Daprodustat is a different approach because it is intended to stimulate erythropoiesis through its mechanism rather than administering ESA injections directly [1].
What side effects are associated with daprodustat?
Commonly reported risks for CKD anemia therapies include effects tied to changes in hemoglobin and overall cardiovascular risk. Specific daprodustat side effects depend on trial data and labeling in each country [1].
Is daprodustat FDA-approved or approved in other countries?
Approval status depends on jurisdiction. Daprodustat has regulatory approval in some markets for CKD-related anemia, with labeling that can include population limits and monitoring recommendations [1].
Who makes daprodustat?
Daprodustat is developed by GlaxoSmithKline (GSK) [1].
What patients typically ask about (monitoring and targets)
Patients and clinicians generally focus on hemoglobin monitoring, iron status, and managing therapy to avoid overshooting hemoglobin targets, since CKD anemia treatments can carry safety concerns when hemoglobin rises too high. The exact monitoring schedule and target ranges follow the local label and clinical practice [1].
What to know about drug availability and insurance coverage
Coverage for CKD anemia medicines often depends on whether a patient is on dialysis, prior ESA use, iron status, and formulary placement. For exact coverage terms, patients usually need their insurer or pharmacy benefit manager to confirm eligibility and prior authorization requirements.
Sources
[1] https://en.wikipedia.org/wiki/Daprodustat